Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00285025 | Study of the Effect of SR57667B in Patients With Alzheimer's Disease | PHASE2 | COMPLETED | 500 | — | — | Mar 1, 2005 | Sep 1, 2005 | Feb 1, 2006 | - | — |
| NCT00285077 | Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease | PHASE2 | COMPLETED | 390 | — | — | Mar 1, 2004 | Nov 1, 2006 | Dec 23, 2008 | 7 | Canada, Denmark +5 |
| Name | Type | Description |
|---|---|---|
| SR57667B | DRUG | - |
Inclusion Criteria: * Male / female outpatients. * Age \> 50 years at screening. * Dementia of Alzheimer's Type (DSM-IV 290.0) according to DSM-IV criteria, Probable AD according to NINCDS-ADRDA criteria, Mini-Mental State Examination score \> 12 and \< 26. * Untreated or treated for a minimum of 6...